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AutopsyAbstract Intra-vesicular Bacillus Calmette–Gue´rin (BCG) immuno-therapy is a cornerstone in the
treatment of superﬁcial bladder carcinoma. However, it can rarely cause BCG-osis, a systemic infec-
tion, potentially fatal. A case of a 73 year old man, diagnosed with superﬁcial urothelial bladder
carcinoma ﬁve months ago, who died with clinical features of septic shock one day after BCG ther-
apeutic maintenance infusion, is presented. The cause of death, BCG-osis, was revealed during
autopsy.
ª 2015 The International Association of Law and Forensic Sciences (IALFS). Production and hosting by
Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
BCG (Bacillus Calmette–Gue´rin) is prepared from a strain of
the attenuated live bovine bacillus, Mycobacterium bovis.1,2
Additional to its use, as a vaccine for the prevention of tuber-
culosis, BCG has therapeutic effects on several conditions such
as leprosy,3 Buruli ulcer4 and several carcinomas. BCG has
been reported for its potency against lung, stomach and col-
orectal cancer, melanoma, ovarian carcinoma and bladder
tumors.5–8 However, if BCG is accidentally given to an
immunocompromised patient, it can cause disseminated or
life-threatening infection.2,9 BCG immunotherapy, is a safe
method10–12 used against recurrence and progression ofsuperﬁcial urothelial carcinoma of the bladder.13 It affects
both healthy urothelial cells and tumor cells14–15 by inducing
a localized type IV hypersensitivity reaction in the bladder
mucosa. It has been postulated that epitopes of BCG bacillus
are presented as antigens on the surface of tumor cells, thus
initiating cell to cell cytotoxicity.15
According to EAU Guidelines non-muscle-invasive urothe-
lial bladder carcinoma patients are stratiﬁed in low, intermedi-
ate and high risk groups in order to estimate their prognosis
and indicate an adequate treatment regimen.16 BCG
immunotherapy is indicated, in intermediate and high risk
tumors. Several studies have proved that it prevents tumor
recurrence and progression after transurethral resection
(TUR) and that is more effective than TUR with adjuvant
chemotherapy.16 The usual induction protocol for BCG instil-
lation is the six-weekly one, followed by a maintenance proto-
col, if needed.17 However, BCG immunotherapy has a greater
complication incidence than intra-vesical chemotherapy and
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BCG-osis is one of them.
The absolute contra-indications of BCG intra-vesical instil-
lation are: recent TUR (less than fourteen days), macroscopic
hematuria, urinary tract infection and traumatic bladder
catheterization.6,16
We present a case of fatal BCG-osis revealed in autopsy.2. Case report
The deceased, a 73 year old white man, was a chronic smoker
who had suffered a myocardial infarct thirty-eight years ago.
He was under anti-hypertensive medication with a combina-
tion of an angiotensin converting enzyme inhibitor plus a thi-
azide diuretic and acetylsalicylic acid. There was no history of
previous pulmonary disease or immunodeﬁciency state. He
was diagnosed with superﬁcial papillary urothelial bladder car-
cinoma 5 months ago, after a TUR. Following this diagnosis,
he underwent intra-vesicular BCG immunotherapy, based on a
weekly and then monthly instillation protocol. He had been
reporting low fever (<38 C) after each therapeutic session,
which remised without medication.
After, his last intra-vesical BCG infusion, he presented with
high fever, fatigue, oliguria, and dysuria. The clinical records
didn’t state any complication during the last instillation
procedure. Due to a progressively deteriorating general
condition, and the presence of an abdominal skin rash, he
was transferred to our hospital the following day. Upon arri-
val, he was already septic, and despite the administration of
adrenaline, broad spectrum antibiotics and corticosteroids,
the patient passed away ten hours later. Certainty about
previous BCG vaccination could not be reached either through
medical records or through relative testimonies. The main
autopsy ﬁndings are summarized below.Figure 1a Large caseating granuloma in the lung parenchyma
(H&E stain ·200).2.1. Macroscopic ﬁndings
A diffuse micro-petechial rash on the abdominal wall was
observed. The examination of the cardiovascular system
revealed critical stenosis in all coronary arteries: 85% of the
lumen was occluded in the left anterior descending artery
and the left circumﬂex artery was almost completely occluded
in its central portion. The heart weighed 420 g, and had a left
type perfusion. Mild concentric hypertrophy of the left ventri-
cle was present. A broad, whitish, scar in the rear wall of the
left ventricle, accompanied with focal wall attenuation was
found. Bold atherosclerotic lesions were present in the aorta,
and particularly in the bifurcation of the abdominal aorta
and also in the common iliac arteries.
The right and left lung weighed 880 g and 860 g respec-
tively, and appeared congestive and edematous. On their pleu-
ral surface were exhibited multiple, yellowish nodules of
maximum diameter 0.1–0.2 cm. Nodules of the same morphol-
ogy were also noted during lung dissection. The liver weighed
2180 g with fatty liver appearance. The gallbladder was ﬁlled
with gallstones.
Focal hyperemia of the bladder mucosa, micro-granular
appearance of the kidneys and few adhesions between the vis-
cera of the pelvic region were also observed.2.2. Histological examination
The histological examination of lung parenchyma, revealed
multiple caseating and non-caseating epithelioid granulomas,
with the presence of Langhans and Touton giant cells
(Figs. 1a and 1b). Diffuse, lymphocytic inﬁltrates were
observed in the pulmonary interstitium. Peripheral emphy-
sema, as well as thickening of alveolar septa were observed.
Focally, amorphous eosinophilic material ﬁlled the alveolar
spaces. Hyperplasia of type II pneumonocytes, and sloughing
of alveolar type I pneumonocytes were present in these regions.
The histologic sections from the coronary arteries, showed
features of activated atherosclerotic plaques. The microscopic
examination of the myocardium, revealed ﬁndings of mild car-
diac hypertrophy, as well as features of previous ischemic
myocardial necrosis and ﬁbrosis in the posterior wall of the left
ventricle and in the posterior portion of the intraventricular
septum.
Severe, fatty degeneration of the liver parenchyma was evi-
dent, along with dense lymphocytic inﬂammatory inﬁltrates in
the portal frames. Focal destruction of hepatocytes and exten-
sion of the inﬂammatory inﬁltrate within the hepatic lobules
were also present. Tiny lymphocytic aggregates were also
observed inside the hepatic lobules. Multiple abscesses with
neutrophil granulocytes, parenchymal necrosis as well as mul-
tiple non-caseating and caseating epithelioid granulomas not
associated with bile ducts were present (Fig. 2). Reactive hep-
atocyte regeneration was evident in the form of bi-nucleated
hepatocytes.
The kidneys presented ﬁndings typical of hypertensive
atherosclerotic disease, with chronic inﬂammatory cells (lym-
phocytes) in the interstitial tissue. The bladder mucosa and
submucosa were moderately inﬁltrated by lymphocytes,
plasma cells and eosinophilic leukocytes. Focally, minute,
non-necrotic epithelioid granulomas were present. In one of
the few places where the transitional epithelium of the bladder
was present, features of hyperplasia with regenerative atypia
were evident. These minute granulomas, may be attributed
to TUR, as well as BCG immunotherapy, so they are not
speciﬁc for BCG-osis. Thin sections of the prostate, revealed
massive necrosis of the organ conﬂuent necrotic granulomas
and epithelioid histiocyte aggregates (Fig. 3).
Figure 1b Non caseating lung granuloma (H&E stain ·200).
Figure 3 Part of large necrotic area in the prostate (H&E stain
·100).
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was performed in sections from the lung and liver parenchyma
where granulomas were evident, but proved negative. PCR for
mycobacterial bacilli was not performed.
The cause of death was attributed to generalized BCG-osis,
on grounds of coronary heart disease and papillary urothelial
carcinoma of the bladder treated with BCG immunotherapy.
The manner of death was certiﬁed as natural.
3. Discussion
The side effects of BCG intra-vesical immunotherapy are usu-
ally mild and short-term, such as abacterial cystitis, dysuria,
hematuria, low fever and usually recede without special treat-
ment.6,12,13 They are also called noninfectious or inﬂammatory
side effects in the literature.12 The major side effects are rela-
tively rare (seen in less than 5% of the patients)10,18–19 and
can be divided in early or late ones, depending on whether
the patient consulted a physician during or after, a 6 month
interval from BCG installation.19 Besides, adverse effects areFigure 2 Liver granuloma (H&E stain ·400).stratiﬁed as local or bladder related, and systemic.20 Both of
them are more frequent during the immediate period after
induction, or in the ﬁrst semester of the maintenance proto-
col.20 There are also side effects nonspeciﬁc to BCG, which
are related with malpractice during the procedure of transure-
thral BCG installation.13
Hepatitis,21 milliary tuberculosis,22 systemic granulomatous
disease,21,23–26 sepsis,12,27–28 allergic reactions,13 and cardiac
toxicity have been reported among BCG serious adverse
effects.29 The most serious side effect of BCG immunotherapy
is BCG-osis or BCG-itis, which is a regularly associated with
traumatic bladder catheterization,6,10,13,30 subsequent
hematogenous dispersion of M. bovis, with multiple organ dis-
function31 and failure. This status may be lethal.13
If a patient with a history of BCG immunotherapy becomes
septic, has fever over 39.5 C or has persistent fever over
38.5 C for more than 24 h, BCG-osis should be suspected.30,32
The therapeutic manipulation under these circumstances con-
sists of multi-drug antituberculous scheme, plus antibiotics
against gram negative bacteria, and corticosteroids.6,13,33 The
mechanism implicated in the above mentioned side effects is
a hypersensitivity response, based on the presence of granulo-
mas, frequently in the absence of microorganisms or real active
dissemination of M. bovis, which is rather unusual.27,34
Furthermore, it must be noted that detection of M. bovis,
by means of Ziehl Neelsen stain or PCR reaction in the spu-
tum, blood, transbronchial or bone marrow biopsy mate-
rial,27,35 is usually negative, and so diagnosis is based on
histopathological ﬁndings and case history.25
In conclusion, attention must be drawn to the afﬁliation of
nurses, physicians and patients with BCG infusion complica-
tions in order to decrease side effects and improve the thera-
peutic procedure.18,24,25 Although BCG administration is
common practice between urologists, usually non urologists
have to deal with BCG side effects.13
Regarding the case presented, none of the above mentioned
contra-indications were present according to the clinical
records. However, the massive necrosis of the prostate as well
as the rapid onset of the disease speaks in favor of a traumatic
bladder catheterization during the last BCG instillation. The
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high persistent fever after BCG maintenance infusion. He
was eventually hospitalized, with septic shock clinical features,
the following day. Although, he received adrenaline, broad
spectrum antibiotics and corticoids, he did not recover. The
cause of death, BCG-osis was revealed by autopsy ﬁndings.
This case stresses the importance of alertness for side effects
of BCG immunotherapy. Patients as well as health profession-
als in general, but also forensic pathologists should be
acquainted with its features.
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